title: Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features.
authors.affiliation: Royal Marsden NHS Foundation Trust, United Kingdom.
authors.forename: Lavinia
authors.initials: L
authors.lastname: Spain
authors.affiliation: Royal Marsden NHS Foundation Trust, United Kingdom.
authors.forename: Thomas
authors.initials: T
authors.lastname: Schmid
authors.affiliation: Royal Marsden NHS Foundation Trust, United Kingdom.
authors.forename: Martin
authors.initials: M
authors.lastname: Gore
authors.affiliation: Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: James.Larkin@rmh.nhs.uk.
authors.forename: James
authors.initials: J
authors.lastname: Larkin
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074324:Ipilimumab; D000077594:Nivolumab; C582435:pembrolizumab